Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BOSTON, Sept. 19, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences in September:
Ladenburg Thalmann Healthcare Conference
Location: Sofitel New York in New York City
Presentation date / time: Tuesday, September 26, 2017 at 9:00 a.m. ET
Cantor Fitzgerald Global Healthcare Conference
Location: InterContinental New York Barclay in New York City
Presentation date / time: Wednesday, September 27, 2017 at 3:25 p.m. ET
A live audio webcast of each presentation will be accessible from the Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to either webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of each webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
